UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 171

Sortiert nach

The foundations of immune checkpoint blockade and the ipilimumab approval decennial

Nature reviews. Drug discovery, 2022-07, Vol.21 (7), p.509-528

2022

Link zum Volltext

Verfügbarkeit prüfen

FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis

Cancer cell, 2015-09, Vol.28 (3), p.285-295

2015

Link zum Volltext

Verfügbarkeit prüfen

Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology

PloS one, 2016-09, Vol.11 (9), p.e0161779

2016

Link zum Volltext

Verfügbarkeit prüfen

Evolving synergistic combinations of targeted immunotherapies to combat cancer

Nature reviews. Cancer, 2015-08, Vol.15 (8), p.457

2015

Link zum Volltext

Verfügbarkeit prüfen

Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy

Clinical cancer research, 2018-10, Vol.24 (20), p.5058-5071

2018

Link zum Volltext

Verfügbarkeit prüfen

Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy

Nature communications, 2019-08, Vol.10 (1), p.3850-13, Article 3850

2019

Link zum Volltext

Verfügbarkeit prüfen

TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection

PLoS pathogens, 2016-01, Vol.12 (1), p.e1005349-e1005349

2016

Link zum Volltext

Verfügbarkeit prüfen

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Journal of clinical oncology, 2010-07, Vol.28 (19), p.3167-3175

2010

Link zum Volltext

Verfügbarkeit prüfen

Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab

Proceedings of the National Academy of Sciences - PNAS, 2017-05, Vol.114 (21), p.E4223-E4232

2017

Link zum Volltext

Verfügbarkeit prüfen

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

Annals of the New York Academy of Sciences, 2013-07, Vol.1291 (1), p.1-13

2013

Link zum Volltext

Verfügbarkeit prüfen

Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape

Cancer immunology research, 2017-02, Vol.5 (2), p.106-117

2017

Link zum Volltext

Verfügbarkeit prüfen

Blockade ofthe negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis

Critical care (London, England), 2013-01, Vol.17 (3), p.R85-R85

2013

Link zum Volltext

Verfügbarkeit prüfen

BMS-936564/MDX-1338: A Fully Human Anti-CXCR4 Antibody Induces Apoptosis In Vitro and Shows Antitumor Activity In Vivo in Hematologic Malignancies

Clinical cancer research, 2013-01, Vol.19 (2), p.357-366

2013

Link zum Volltext

Verfügbarkeit prüfen

FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis

Cancer cell, 2015-10, Vol.28 (4), p.543-543

2015

Link zum Volltext

Verfügbarkeit prüfen

An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients

PloS one, 2018-06, Vol.13 (6), p.e0198158

2018

Link zum Volltext

Verfügbarkeit prüfen

Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Journal of clinical oncology, 2023-02, Vol.41 (4), p.715-723

2023

Link zum Volltext

Verfügbarkeit prüfen

Checkpoint Blockade in Cancer Immunotherapy

Advances in Immunology, 2006-01, Vol.90, p.297-339

2006

Link zum Volltext

Verfügbarkeit prüfen

Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs

International immunology, 2007-10, Vol.19 (10), p.1223-1234

2007

Link zum Volltext

Verfügbarkeit prüfen

Cutting edge: accelerated autoimmune diabetes in the absence of LAG-3

The Journal of immunology (1950), 2011-10, Vol.187 (7), p.3493-3498

2011

Link zum Volltext

Verfügbarkeit prüfen

TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer

Oncoimmunology, 2020-01, Vol.9 (1), p.1843247-1843247

2020

Link zum Volltext

Verfügbarkeit prüfen

Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors

Oncoimmunology, 2018-05, Vol.7 (5), p.e1421891-e1421891

2018

Link zum Volltext

Verfügbarkeit prüfen

Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV + Cancers

Cancer immunology research, 2020-01, Vol.8 (1), p.131-145

2020

Link zum Volltext

Verfügbarkeit prüfen

Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models

Oncoimmunology, 2018-01, Vol.7 (1), p.e1377873-e1377873

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 171

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(169)
Mit Volltextzugriff
(159)

Publikationsform

Artikel
(171)

Sprache

Englisch
(171)
Japanisch
(30)

Erscheinungsjahr

n.n

Thema

Science & Technology
(107)
Life Sciences & Biomedicine
(93)
Humans
(84)
Animals
(46)
Female
(36)
Mice
(36)
Oncology
(36)
Biological And Medical Sciences
(35)
Immunology
(33)
Male
(31)
Immunotherapy
(27)
Medical Sciences
(26)
Tumors
(25)
Dermatology
(23)
Cancer
(22)
Adult
(19)
Antibodies, Monoclonal - Therapeutic Use
(19)
Cell Line, Tumor
(18)
Middle Aged
(18)
Melanoma
(17)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The foundations of immune checkpoint blockade and the ipilimumab approval decennial

FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis

Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology

Evolving synergistic combinations of targeted immunotherapies to combat cancer

Elective Nodal Irradiation Attenuates the Combinatorial Efficacy of Stereotactic Radiation Therapy and Immunotherapy

Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy

TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab

A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape

Blockade ofthe negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis

BMS-936564/MDX-1338: A Fully Human Anti-CXCR4 Antibody Induces Apoptosis In Vitro and Shows Antitumor Activity In Vivo in Hematologic Malignancies

FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 Axis

An open-label, multiple ascending dose study of the anti-CTLA-4 antibody ipilimumab in viremic HIV patients

Anticancer immunotherapy by CTLA-4 blockade： obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25

Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

Checkpoint Blockade in Cancer Immunotherapy

Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs

Cutting edge: accelerated autoimmune diabetes in the absence of LAG-3

TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer

Complimentary mechanisms of dual checkpoint blockade expand unique T-cell repertoires and activate adaptive anti-tumor immunity in triple-negative breast tumors

Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV + Cancers

Interleukin-21 combined with PD-1 or CTLA-4 blockade enhances antitumor immunity in mouse tumor models

Suchergebnisse filtern